CL002-NK

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameCL002-NK
Drug Alias Nameanti GPC-3 CAR NK cellsCAR NK细胞CXT-CAR NK细胞CL002NKCL002-NK +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Oriental Hepatobiliary Surgery Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Oriental Hepatobiliary Surgery Hospital
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A